NICE estimates that 1,000 women could benefit from Ryeqo, which can be taken once-daily up until the menopause.

Gedeon Richter's drug is the only licensed GnRH antagonist option and, unlike GnRH agonists like Takeda's Prostap ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Endometriosis affects millions of people - and this new breakthrough treatment could be a game-changer for some ...

Gedeon Richter acquired rights to the drug earlier that year in Europe, Russia and the Commonwealth of Independent States (CIS), Latin America, Australia, and New Zealand.

The NICE has approved the first daily oral treatment for endometriosis symptoms for use within the NHS in England.

A daily pill for endometriosis will be offered to around 1,000 women on the NHS, marking a “step-change” in treatment for the ...

Nice initially rejected the drug, but new evidence was provided by the manufacturer Gedeon Richter to address questions about ...

It could provide relief for around 1,000 women in England each year who suffer from this debilitating condition ...